<?xml version='1.0' encoding='utf-8'?>
<document id="20642555"><sentence text="Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjects."><entity charOffset="70-79" id="DDI-PubMed.20642555.s1.e0" text="bupropion" /><entity charOffset="107-125" id="DDI-PubMed.20642555.s1.e1" text="4-hydroxybupropion" /><pair ddi="false" e1="DDI-PubMed.20642555.s1.e0" e2="DDI-PubMed.20642555.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20642555.s1.e0" e2="DDI-PubMed.20642555.s1.e1" /></sentence><sentence text="Woohwangcheongsimwon suspension has traditionally been used for the treatment and prevention of stroke, hypertension, palpitations, convulsions and unconsciousness in various Asian countries" /><sentence text=" Woohwangcheongsimwon suspensions showed an inhibitory effect on CYP2B6 activity in vitro" /><sentence text=" Two terpenoids, borneol and isoborneol, are major constituents of woohwangcheongsimwon suspension, and show a competitive inhibition of CYP2B6 with K(i) values of 9"><entity charOffset="5-15" id="DDI-PubMed.20642555.s4.e0" text="terpenoids" /><entity charOffset="17-24" id="DDI-PubMed.20642555.s4.e1" text="borneol" /><entity charOffset="29-39" id="DDI-PubMed.20642555.s4.e2" text="isoborneol" /><pair ddi="false" e1="DDI-PubMed.20642555.s4.e0" e2="DDI-PubMed.20642555.s4.e0" /><pair ddi="false" e1="DDI-PubMed.20642555.s4.e0" e2="DDI-PubMed.20642555.s4.e1" /><pair ddi="false" e1="DDI-PubMed.20642555.s4.e0" e2="DDI-PubMed.20642555.s4.e2" /><pair ddi="false" e1="DDI-PubMed.20642555.s4.e1" e2="DDI-PubMed.20642555.s4.e1" /><pair ddi="false" e1="DDI-PubMed.20642555.s4.e1" e2="DDI-PubMed.20642555.s4.e2" /></sentence><sentence text="5 and 5" /><sentence text="9 microM, respectively" /><sentence text=" Bupropion undergoes metabolic transformation to the active metabolite, 4-hydroxybupropion, primarily via CYP2B6 both in vivo and in vitro"><entity charOffset="1-10" id="DDI-PubMed.20642555.s7.e0" text="Bupropion" /><entity charOffset="72-90" id="DDI-PubMed.20642555.s7.e1" text="4-hydroxybupropion" /><pair ddi="false" e1="DDI-PubMed.20642555.s7.e0" e2="DDI-PubMed.20642555.s7.e0" /><pair ddi="false" e1="DDI-PubMed.20642555.s7.e0" e2="DDI-PubMed.20642555.s7.e1" /></sentence><sentence text=" It is often used as a CYP2B6 substrate for clinical drug-drug interaction studies" /><sentence text=" Drug interactions may occur between woohwangcheongsimwon suspension and bupropion"><entity charOffset="73-82" id="DDI-PubMed.20642555.s9.e0" text="bupropion" /></sentence><sentence text="" /><sentence text="Co-administration with woohwangcheongsimwon suspension did not alter the pharmacokinetics of bupropion or its metabolite, 4-hydroxybupropion"><entity charOffset="93-102" id="DDI-PubMed.20642555.s11.e0" text="bupropion" /><entity charOffset="122-140" id="DDI-PubMed.20642555.s11.e1" text="4-hydroxybupropion" /><pair ddi="false" e1="DDI-PubMed.20642555.s11.e0" e2="DDI-PubMed.20642555.s11.e0" /><pair ddi="false" e1="DDI-PubMed.20642555.s11.e0" e2="DDI-PubMed.20642555.s11.e1" /></sentence><sentence text=" Dosage adjustment of bupropion is unnecessary in patients concomitantly administered the highest recommended daily dose of woohwangcheongsimwon suspension"><entity charOffset="22-31" id="DDI-PubMed.20642555.s12.e0" text="bupropion" /></sentence><sentence text="" /><sentence text="To examine the effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, formed via CYP2B6 in vivo"><entity charOffset="85-94" id="DDI-PubMed.20642555.s14.e0" text="bupropion" /><entity charOffset="122-140" id="DDI-PubMed.20642555.s14.e1" text="4-hydroxybupropion" /><pair ddi="false" e1="DDI-PubMed.20642555.s14.e0" e2="DDI-PubMed.20642555.s14.e0" /><pair ddi="false" e1="DDI-PubMed.20642555.s14.e0" e2="DDI-PubMed.20642555.s14.e1" /></sentence><sentence text="" /><sentence text="A two-way crossover clinical trial with a 2 week washout period was conducted in 14 healthy volunteers" /><sentence text=" In phases I and II, subjects received 150 mg bupropion with or without woohwangcheongsimwon suspension four times (at -0"><entity charOffset="46-55" id="DDI-PubMed.20642555.s17.e0" text="bupropion" /></sentence><sentence text="17, 3" /><sentence text="5, 23" /><sentence text="5 and 47" /><sentence text="5 h, with the time of bupropion administration taken as 0 h) in a randomized balanced crossover order"><entity charOffset="22-31" id="DDI-PubMed.20642555.s21.e0" text="bupropion" /></sentence><sentence text=" Bupropion and 4-hydroxybupropion plasma concentrations were measured for up to 72 h by LC-MS/MS"><entity charOffset="1-10" id="DDI-PubMed.20642555.s22.e0" text="Bupropion" /><entity charOffset="15-33" id="DDI-PubMed.20642555.s22.e1" text="4-hydroxybupropion" /><pair ddi="false" e1="DDI-PubMed.20642555.s22.e0" e2="DDI-PubMed.20642555.s22.e0" /><pair ddi="false" e1="DDI-PubMed.20642555.s22.e0" e2="DDI-PubMed.20642555.s22.e1" /></sentence><sentence text=" Urine was collected up to 24 h to calculate the renal clearance" /><sentence text=" In addition, the CYP2B6*6 genotype was also analyzed" /><sentence text="" /><sentence text="The geometric mean ratios and 90% confidence interval of bupropion with woohwangcheongsimwon suspension relative to bupropion alone were 0"><entity charOffset="57-66" id="DDI-PubMed.20642555.s26.e0" text="bupropion" /><entity charOffset="116-125" id="DDI-PubMed.20642555.s26.e1" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.20642555.s26.e0" e2="DDI-PubMed.20642555.s26.e0" /><pair ddi="false" e1="DDI-PubMed.20642555.s26.e0" e2="DDI-PubMed.20642555.s26.e1" /></sentence><sentence text="976 (0" /><sentence text="917, 1" /><sentence text="04) for AUC(0,infinity) and 0" /><sentence text="948 (0" /><sentence text="830,1" /><sentence text="08) for C(max), respectively" /><sentence text=" The corresponding values for 4-hydroxybupropion were 0"><entity charOffset="30-48" id="DDI-PubMed.20642555.s33.e0" text="4-hydroxybupropion" /></sentence><sentence text="856 (0" /><sentence text="802, 0" /><sentence text="912) and 0" /><sentence text="845 (0" /><sentence text="782, 0" /><sentence text="914), respectively" /><sentence text=" The t(max) values of bupropion and 4-hydroxybupropion were not significantly different between the two groups (P &gt; 0"><entity charOffset="22-31" id="DDI-PubMed.20642555.s40.e0" text="bupropion" /><entity charOffset="36-54" id="DDI-PubMed.20642555.s40.e1" text="4-hydroxybupropion" /><pair ddi="false" e1="DDI-PubMed.20642555.s40.e0" e2="DDI-PubMed.20642555.s40.e0" /><pair ddi="false" e1="DDI-PubMed.20642555.s40.e0" e2="DDI-PubMed.20642555.s40.e1" /></sentence><sentence text="05)" /><sentence text=" The pharmacokinetic parameters of bupropion and 4-hydroxybupropion were unaffected by woohwangcheongsimwon suspension"><entity charOffset="35-44" id="DDI-PubMed.20642555.s42.e0" text="bupropion" /><entity charOffset="49-67" id="DDI-PubMed.20642555.s42.e1" text="4-hydroxybupropion" /><pair ddi="false" e1="DDI-PubMed.20642555.s42.e0" e2="DDI-PubMed.20642555.s42.e0" /><pair ddi="false" e1="DDI-PubMed.20642555.s42.e0" e2="DDI-PubMed.20642555.s42.e1" /></sentence><sentence text="" /><sentence text="These results indicate that woohwangcheongsimwon suspension has a negligible effect on the disposition of a single dose of bupropion in vivo"><entity charOffset="123-132" id="DDI-PubMed.20642555.s44.e0" text="bupropion" /></sentence><sentence text=" As a result, temporary co-administration with woohwangcheongsimwon suspension does not seem to require a dosage adjustment of bupropion"><entity charOffset="127-136" id="DDI-PubMed.20642555.s45.e0" text="bupropion" /></sentence><sentence text="" /></document>